Division of Core Clinical Laboratory Services Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Division of Biostatistics Department of Health Sciences Research Mayo Clinic College of Medicine Rochester, MN.
Clin Chem. 2020 Nov 1;66(11):1444-1449. doi: 10.1093/clinchem/hvaa203.
The necessity of individual tests within the most commonly used disease-oriented test panels has not been well established. We evaluated test-ordering practices for total calcium, both before and after implementation of American Medical Association (AMA)-approved panels (basic metabolic panel [BMP] and comprehensive metabolic panel [CMP]) in our electronic ordering system.
We performed a retrospective review of all total calcium orders placed during April and June 2018, before and after implementation of the panels. Orders from inpatient, outpatient, and emergency department (ED) care units were totaled, and the percentage of abnormal test results was calculated. We then queried institutional databases to determine the number of unique patients with calcium-related diagnoses and compared the rates from a 5-month period both before and after implementation of the panels.
Total test volumes and tests per unique patient increased by more than 3-fold after implementation of calcium-containing AMA-approved panels, with the majority of those orders coming from BMPs and CMPs. The rate of low calcium values increased because of the shift toward more inpatient testing; however, the percentage of abnormal results within each patient population (inpatient, outpatient, ED) decreased. The prevalence of hypo- and hypercalcemia-related diagnoses among patients in the 5 months after implementation did not change significantly (1.29% before implementation vs 1.27% after implementation).
Implementation of BMPs and CMPs dramatically increased total calcium testing volumes without changing the rate of calcium-related diagnoses. The results suggest that the increase in total calcium orders associated with panel-based testing largely constitutes excess or unnecessary testing.
在最常用的面向疾病的检测组合中,个别检测的必要性尚未得到充分证实。我们评估了在我们的电子医嘱系统中实施美国医学协会(AMA)批准的检测组合(基本代谢检测组合[BMP]和综合代谢检测组合[CMP])前后,总钙的医嘱情况。
我们对 2018 年 4 月和 6 月实施检测组合前后所有总钙医嘱进行了回顾性分析。总计了住院、门诊和急诊(ED)护理单元的医嘱,并计算了异常检测结果的百分比。然后,我们查询了机构数据库,以确定与钙相关诊断的患者数量,并比较了实施检测组合前后 5 个月的比率。
在实施含钙的 AMA 批准检测组合后,总检测量和每位患者的检测次数增加了 3 倍以上,其中大部分来自 BMP 和 CMP。由于向更多的住院患者检测转移,低钙值的比例增加了;但是,每个患者群体(住院、门诊、ED)的异常结果百分比都降低了。实施后 5 个月内,低钙血症和高钙血症相关诊断的患病率没有显著变化(实施前为 1.29%,实施后为 1.27%)。
BMP 和 CMP 的实施大大增加了总钙检测量,而钙相关诊断的比例没有改变。结果表明,与基于检测组合的检测相关的总钙医嘱的增加主要构成了多余或不必要的检测。